Startup raises $23m for flesh-eating bacteria drug
The proceeds will be used for a late-stage clinical study for treating what is commonly known as 'flesh-eating bacteria' and other severe infections.
Atox Bio, a biotech startup that traces its origins to Hebrew University, said yesterday it has raised $23 million from an investment group led by SR One, the venture capital arm of the British drug company GlaxoSmithKline.
register with haaretz
Like us on Facebook and get articles directly in your news feed